Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms.
about
Eating disorders in schizophrenia: implications for research and managementAlterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gainFunctional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmissionPharmacological interventions for reducing weight gain in schizophreniaBehavioural interventions for reducing weight gain in schizophreniaManagement of antipsychotic-related weight gainAripiprazole partial agonism at 5-HT2C: a comparison of weight gain associated with aripiprazole adjunctive to antidepressants with high versus low serotonergic activitiesRole of endoplasmic reticulum stress in drug-induced toxicityMetabolic issues in patients affected by schizophrenia: clinical characteristics and medical managementEffect of atypical antipsychotics on fetal growth: is the placenta involved?Dopamine receptors - IUPHAR Review 13Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and FutureOlanzapine-induced hyperphagia and weight gain associate with orexigenic hypothalamic neuropeptide signaling without concomitant AMPK phosphorylationHealth risks and changes in self-efficacy following community health screening of adults with serious mental illnessesExtracting antipsychotic polypharmacy data from electronic health records: developing and evaluating a novel process.Bariatric endocrinology: principles of medical practice.The potential role of appetite in predicting weight changes during treatment with olanzapine.Dopamine D2 receptors and the circadian clock reciprocally mediate antipsychotic drug-induced metabolic disturbances.Time-dependent changes and potential mechanisms of glucose-lipid metabolic disorders associated with chronic clozapine or olanzapine treatment in ratsClassics in Chemical Neuroscience: Aripiprazole.Atypical antipsychotics and metabolic syndrome in patients with schizophrenia: risk factors, monitoring, and healthcare implications.Improving metabolic and cardiovascular health at an early psychosis intervention program in vancouver, CanadaComparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties.5-HT radioligands for human brain imaging with PET and SPECTNovel olanzapine analogues presenting a reduced H1 receptor affinity and retained 5HT2A/D2 binding affinity ratio.Second generation antipsychotic-induced type 2 diabetes: a role for the muscarinic M3 receptor.Obesity and cognitive decline: role of inflammation and vascular changes.Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.Association of genetic variants of the histamine H1 and muscarinic M3 receptors with BMI and HbA1c values in patients on antipsychotic medicationIn vivo pharmacological evaluations of novel olanzapine analogues in rats: a potential new avenue for the treatment of schizophreniaDramatic weight loss associated with commencing clozapine.Ziprasidone with adjunctive mood stabilizer in the maintenance treatment of bipolar I disorder: long-term changes in weight and metabolic profilesAcute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat.Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.Comparative Pharmacology of Risperidone and Paliperidone.DNA methylation, insulin resistance and second-generation antipsychotics in bipolar disorder.The role of leptin in antipsychotic-induced weight gain: genetic and non-genetic factorsRecent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs.Clozapine and risperidone influence on cortisol and estradiol levels in male patients with schizophrenia.
P2860
Q21284525-2E8158C0-9507-401D-A34E-ADC183EF6EE9Q21561008-5FFCCF26-5115-4B63-89D7-407BEF93DAC1Q23913269-F06ED65F-E5E1-434E-AB84-95FCCF5B2E8BQ24194410-21632D69-A531-461D-81F1-095FCC4A372DQ24197824-2FB21380-BBB4-4A20-AE62-E9F09B6C8D1BQ24610124-54205A2C-8804-4D26-8FEF-E9E814019295Q24615556-030A19AA-CFD0-46D4-ACF7-AF11B6D653F2Q26765518-3EC181A8-DF90-4916-9C72-EE77560AA678Q26783003-375C3157-9A4F-4910-A1CA-1E53D841B030Q27012948-45BBF5A0-487F-4210-AF03-B264C890FB29Q28256783-2EC68E1F-BC8D-4980-B83E-E9C6F55482B6Q28394341-5247A7A0-7D7C-446B-AFBC-8E86236E7D37Q28478539-97A358BB-1B18-436F-92B5-9D1DAD717FDCQ28546182-C9F7D6CD-CA82-4FE4-B53D-9147A563B07FQ30981989-198B421F-4DA4-4BDA-9A2A-5679183B7BA5Q33677790-6DA2E44D-445F-4230-A868-447D99D49CD3Q33692484-04C479FB-859C-4484-BFB8-2A0C4325496AQ33718801-1644194C-6A81-4AB4-B6BC-2CE2C286C89FQ33765864-B2F86643-01C2-46FD-B3AB-330428875179Q33866125-D01CF902-D543-4A53-A532-C6D2DA23FBBCQ33928935-90B7C42F-EE1A-4D9D-8A37-40F1442616C6Q34139645-DF73A2F0-358B-4D7F-AF08-C2C7E72BE774Q34169978-C96F9D83-5D90-4BC8-B666-4ABE5BAAC7D3Q34192729-5A3B59A0-6E95-4969-8377-74F2E2732C6FQ34314781-3D36D4A6-E924-4462-87F2-9D3EBCFA38B4Q34376884-58238320-0E52-45C1-B65E-4741A2EFC464Q34540572-1721265F-2274-4D73-9BBB-B2DABE00030FQ34623350-03C6B1F7-5428-46AA-8DC4-5244FCEA18AAQ34641561-BF788DCA-A46F-4A2C-9E8B-EA654EC9184DQ35064650-FC38D672-D7DE-4BAF-8C20-3CF091B80531Q35069463-34CF1007-5199-45FF-8B69-361D3850B50CQ35544391-3D22855C-6C3A-4BE9-BE79-8CEE2330C899Q35577365-738EA5BF-D772-4E8A-8A58-D663A42AB386Q35675775-13A4FF03-0AB1-4E58-B8EA-05E7E0C8800FQ35754726-610EF29A-D40C-4E7E-B221-C042213A6081Q35807345-4AABF435-FCFB-4097-860A-26A86AA560A8Q35848001-B5E3314C-0767-49AA-88FE-1B9922E0793EQ35864617-45568D5A-AEE2-48F0-975F-FBD7A7D14E8DQ36063735-64246C9B-32CA-4741-8682-9AB8549AE019Q36310008-7B6F2053-E068-4875-AD4A-FAB496D4C465
P2860
Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms.
@ast
Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms.
@en
type
label
Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms.
@ast
Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms.
@en
prefLabel
Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms.
@ast
Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms.
@en
P1476
Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms.
@en
P2093
Gavin P Reynolds
Shona L Kirk
P304
P356
10.1016/J.PHARMTHERA.2009.10.010
P577
2009-11-17T00:00:00Z